Opioid Drugs: Global Markets to 2023
NEW YORK, Dec. 3, 2018 /PRNewswire/ -- Report Scope:
The current report offers a detailed picture of the prescription opioid drug market.Prescription opioids are included in the scope of study; illegal opioids such as heroin, which are sold in illegal market for illicit usage, are not included.
Read the full report: https://www.reportlinker.com/p05638983
The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.
This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics.
The report details market shares of opioid drugs based on product and geography.Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol and others.
Each product segment includes detailed analyses covering an overview of drug, mechanism of action and market insights on each drug.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, the U.K. France, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
- 20 data tables and 38 additional tables
- An overview of the global market for opioid drugs
- Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of types, mode of action and receptor target of opioids drugs i.e. Mu receptor, Delta receptor and Kappa receptor
- Details of technological advancement for new opioid formulation to reduce the risk of drug abuse
- Case study of opioid addiction, opioid abuse and overdose and significant events addressing opioid misuse and abuse
- Information on stringent regulatory policies and government guidelines to impede the adoption rate of the opioid drugs
- Insights of new safety measures announced for immediate release (IR) opioids and CDC guidelines on prescribing opioids for chronic pain
- Company profiles of the major players of the market, including Acura Pharmaceuticals Inc., Cipher Pharmaceutical Inc., Daiichi Sankyo Inc., Johnson & Johnson, Lupin Ltd., Pfizer Inc., Sun Pharmaceuticals and Teva Pharmaceutical Industries Ltd.
Summary
The global market for opioid drugs was valued at REDACTED in 2017.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED by 2023.
Growth of the global market is attributed to the factors such as the growing prevalence of cancer, high demand for pain therapeutics in treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and growing approval rate of abuse deterrent formulations of opioid drugs.
The opioid drug market is a fragmented market with numerous small and large players. Market players are investing in the development of novel therapeutics, which is anticipated to drive the market during the forecast period.
The global opioid drug market is segmented based on the product and region.
Report Scope:
The current report offers a detailed picture of the prescription opioid drug market.Prescription opioids are included in the scope of study; illegal opioids such as heroin, which are sold in illegal market for illicit usage, are not included.
The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.
This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics.
The report details market shares of opioid drugs based on product and geography.Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol and others.
Each product segment includes detailed analyses covering an overview of drug, mechanism of action and market insights on each drug.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, the U.K. France, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
- 20 data tables and 38 additional tables
- An overview of the global market for opioid drugs
- Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of types, mode of action and receptor target of opioids drugs i.e. Mu receptor, Delta receptor and Kappa receptor
- Details of technological advancement for new opioid formulation to reduce the risk of drug abuse
- Case study of opioid addiction, opioid abuse and overdose and significant events addressing opioid misuse and abuse
- Information on stringent regulatory policies and government guidelines to impede the adoption rate of the opioid drugs
- Insights of new safety measures announced for immediate release (IR) opioids and CDC guidelines on prescribing opioids for chronic pain
- Company profiles of the major players of the market, including Acura Pharmaceuticals Inc., Cipher Pharmaceutical Inc., Daiichi Sankyo Inc., Johnson & Johnson, Lupin Ltd., Pfizer Inc., Sun Pharmaceuticals and Teva Pharmaceutical Industries Ltd.
Read the full report: https://www.reportlinker.com/p05638983
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/opioid-drugs-global-markets-to-2023-300759115.html
SOURCE Reportlinker
